Thursday, December 23, 2021
Omicron IS milder, another study finds: New variant is 80 PER CENT less likely to lead to hospitalistion than Delta, according to real-world South African research
People who catch Omicron are 80 per cent less likely to be hospitalised than those who get Delta, a major study from South Africa suggests.
The real-world analysis, of more than 160,000 people, comes ahead of a similar UK Government report expected to show Britons are also less likely to be severely ill with the variant.
Omicron sufferers were also 70 per cent less likely to be admitted to ICU or put on a ventilator compared to those with Delta, according to the study led by South Africa's National Institute for Communicable Diseases (NICD).
South African doctors have insisted for weeks that Omicron is milder since raising the alarm about it on November 24 and accused the UK of panicking about Omicron.
But the researchers at the NICD who carried out the study, which has not been peer-reviewed yet, said it still doesn't answer whether Omicron is intrinsically weaker than Delta.
'It is difficult to disentangle the relative contribution of high levels of previous population immunity versus intrinsic lower virulence to the observed lower disease severity,' the researchers concluded.
Built-up immunity from three previous waves of the virus and vaccines are believed to be doing most of the heavy lifting in keeping patients out of hospital this time around.
Up to 70 per cent of South Africans are believed to have had Covid before and only around a quarter are double vaccinated, with boosters not widely available yet.
Omicron cases in South Africa yesterday fell for the fourth day in a row, while the UK's daily cases have been flat at around 90,000 for six days.
South Africa's hospital admissions are hovering at below 400 per day, on average, and dropped by 5 per cent in a week yesterday. In the UK, hospital rates have been mostly flat since late summer, with around 900 per day.
That's despite gloomy Government modelling warning that 1million Britons could be catching the virus daily by the end of the year.
Professor Paul Hunter, an expert in infectious diseases at the University of East Anglia, described the South African study as important and said it was the first properly conducted study to appear in pre-print form on the issue of Omicron versus Delta severity.
But Professor Hunter said its main weakness was that it compared Omicron data from one period with Delta data from an earlier period.
Omicron continues to fade in ground zero South Africa
Daily Covid cases in South Africa have fallen for the fourth day in a row as Omicron continues to fade in the variant's epicentre.
Data from the National Institute For Communicable Diseases (NICD) shows 15,424 South Africans tested positive in the last 24 hours, down by a third on the nearly 24,000 cases confirmed last Tuesday.
A fifth fewer people were tested for the first in the last 24 hours compared to the same period last week, but test positivity — the proportion of those tested who are infected — has been trending downwards for eight days.
But hospitalisations and deaths – which lag two to three weeks behind the pattern seen in case numbers due to the delay in an infected person becoming seriously unwell – have risen.
More than 630 people were hospitalised across the country, up only 5 per cent in a week but the highest daily number in the country's fourth wave.
The previous record was last Wednesday when 620 people were hospitalised. Meanwhile 35 deaths were recorded, a 46 per cent uptick on last Tuesday.
The falling case numbers come despite only 25 per cent of South Africans being double-jabbed and boosters not being dished out in the country.
The analysis was carried out by a group of scientists from the National Institute for Communicable Diseases (NICD) and major universities including University of the Witwatersrand and University of KwaZulu-Natal.
They used data from four sources: national COVID-19 case data reported to the NICD, public sector laboratories, one large private sector lab and genome data for clinical specimens sent to NICD from private and public diagnostic labs across the country.
They compared data on Omicron infections in October and November with data about Delta infections between April and November, all in South Africa.
A case was considered to be Omicron if the positive test did not detect part of the virus' cell - a tell-tale signal for Omicron due to its extensive mutations - and a high amount of the virus in the sample.
And a hospitalisation was linked with a positive case if a person was admitted to hospital between seven and 21 days of testing positive.
A patient was considered to have severe disease if they were admitted to ICU, required mechanical ventilation, received an oxygen treatment, fluid leaked into their lung or died.
Their study, which has not been peer-reviewed and was published on pre-print website medRxiv, found that among the 10,547 Omicron cases identified between October 1 and November 30, 261 (2.5 per cent) were admitted to hospital.
For comparison, among the 948 non-Omicron cases in the same period - almost all of which would have been Delta, which was behind 95 per cent of cases before Omicron emerged - 121 people were hospitalised (12.8 per cent).
After adjusting for other factors, the researchers said shows that those who caught Omicron had a 80 per cent lower risk of requiring hospital care.
Among those hospitalised with either strain in the nine-week period, the severity of illness was the same, with 317 of the 382 patients (83 per cent) discharged by December 21.
But comparing Omicron hospitalisations with Delta hospitalisations earlier this year, the scientists found Omicron patients were less likely to suffer from severe disease.
Since the beginning of the pandemic, 1,734 people in South Africa have been hospitalised whose test was genomically sequenced as either Alpha, Beta, Delta or Omicron.
The researchers also found that Omicron patients had much higher viral loads compared to Delta infections, echoing recent studies and data that the strain is more transmissible.
The researchers noted that around seven in 10 South Africans had already been infected with Covid by November when Omicon hit, while a quarter of its population is double-jabbed.
It is 'difficult to disentangle' how much previous infection and vaccines contribute to high levels of immunity against hospitalisation and severe illness from Omicron and how much is due to Omicron itself being less severe, the experts said.
Because there is no difference in Covid severity among Omicron and Delta patients hospitalised in the last two months, it is likely that the reduced severity of Omicron 'may be in part a result of high levels of population immunity' due to previous infection or vaccination, the researchers said.
It comes after a separate real-world study of 78,000 Omicron cases in South Africa found the risk of hospitalisation was a fifth lower than with Delta and 29 per cent lower than the original virus.
As a crude rate, Omicron is led to a third fewer hospital admissions than Delta did during its entire wave — 38 admissions per 1,000 Omicron cases compared to 101 per 1,000 for Delta.
The study also found two doses of Pfizer's vaccine still provide 70 per cent protection against hospital admission or death from Omicron, compared to 93 per cent for Delta.
While this is more protection than many scientists initially feared, it still leaves 30 per cent of people vulnerable to severe Omicron disease, four times as many as Delta.
Waning immunity from two Pfizer doses was found to offer just 33 per cent protection against Omicron infection, explaining why the country has seen a meteoric rise in case numbers.
***************************************************
Single vaccine for all COVID variants undergoing human trials
Scientists at the US Army’s Walter Reed Army Institute of Research are expected to announce the results of human trials of a single vaccine for all COVID variants in coming weeks.
Defense One reported that Dr Kayvon Modjarrad, director of Walter Reed’s infectious diseases branch, said Phase 1 of human trials of the “Spike Ferritin Nanoparticle” COVID-19 vaccine had positive results.
The trials tested the vaccine against Omicron and other variants, the US publication reported. The human trial followed successful animal trials completed earlier this year.
The new type of vaccine has been under development by the US Army since early 2020 when the Army lab received its first DNA sequencing of the COVID-19 virus.
Researchers believe the vaccine will potentially protect not only against the virus and variants responsible for the current COVID-19 pandemic, but also against other respiratory viruses such as Severe Acute Respiratory Syndrome, or SARS.
The “Spike Ferritin Nanoparticle” (SpFN) vaccine employs the common protein ferritin in the form of a soccer ball-shaped “platform”.
The platform has 24 “faces” onto which are attached replicas of the spike proteins used by some viruses, including coronaviruses, to break into cells.
Delivering spike replicas via vaccines teaches the immune system to recognise and attack them in case of infection.
In lab experiments, antibodies induced by the vaccine protected mice from what would otherwise have been lethal doses of the virus that causes COVID-19 and also of the virus that caused the 2003 SARS outbreak, researchers said on in Cell Reports on December 7.
“Presenting multiple copies of spike in an ordered fashion may be the key to inducing a potent and broad immune response,” said study leader Gordon Joyce of the Walter Reed Army Institute of Research in Silver Spring, Maryland said at the time.
The vaccine would remain stable at a wide range of temperatures, he said, making it especially useful in areas without specialised storage equipment.
********************************************
Doctor Says He Was Fired for Trying to Treat COVID-19 Patients With Ivermectin
A Mississippi doctor said he was fired for attempting to treat COVID-19 patients with ivermectin, which is approved by the Food and Drug Administration (FDA) to treat parasites, although the hospital in question said he was not an employee but instead was an independent contractor.
Dr. John Witcher, an emergency room physician at the Baptist Memorial Hospital in Yazoo City, said was “told not to come back” after taking several COVID-19 patients off Remdesivir, which is approved by the FDA to treat the virus, and allowed them to use ivermectin.
“I was very surprised that I was basically told to not come back at the end of the day,” Witcher said on the Stew Peters podcast. “These patients were under my direct care, and so I felt like taking them off Remdesivir and putting them on ivermectin was the right thing to do at the time.”
Baptist Memorial told news outlets that Witcher “no longer practices medicine as an independent physician” at the Yazoo City facility, adding that he was an independent contractor, not an employee at the facility.
The hospital system said that it follows “the standards of care recommended by the scientific community and our medical team in the prevention and treatment of COVID-19” such as vaccines and monoclonal antibody treatments.
But Witcher said that he was working at the Baptist Memorial emergency room when three new COVID-19 patients arrived on Dec. 10. They were prescribed Remdesivir, but Witcher said that he has concerns about the drug.
“I was there at the hospital for three days straight in the ER and so I felt like this would be a good opportunity to try ivermectin on these inpatient patients that I had been following very closely and just see how well it worked,” Witcher remarked.
*********************************************
Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS)
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Wednesday, December 22, 2021
‘Negligible benefit’: Experts urge South Africa to end quarantine and contact tracing
Leading South African doctors advising the government’s Covid-19 response have called for quarantine and contact tracing to be stopped immediately, saying the measures are of “negligible public health benefit”.
The Ministerial Advisory Committee (MAC) on Covid-19, co-chaired by Professors Koleka Mlisana and Marian Jacobs, wrote to South African Health Minister Joe Phaahla on Thursday to argue that existing quarantine and contact tracing protocols were “outdated” and no longer effective containment measures.
The MAC pointed out that only a very small proportion of Covid-19 cases were detected through testing, as up to 84 per cent of cases were estimated to be asymptomatic.
“It stands to reason that if the vast majority of cases are not diagnosed, then the vast majority of case contacts are also not diagnosed,” Profs Mlisana and Jacobs wrote.
“This means that quarantining and contact tracing are of negligible public health benefit in the South African setting.”
South Africa introduced a 14-day quarantine period for “high risk” contacts of Covid-19 patients in early 2020. This was later reduced to 10 days.
“Since then, several changes to the Covid-19 situation have occurred,” they wrote. “The proportion of people with immunity to Covid-19 (from infection and/or vaccination) has risen substantially, exceeding 60-80 per cent in several serosurveys.
“We have learned more about the manner in which Covid-19 is spread, and also now have to contend with variants of concern whose epidemiology differs from that of the ancestral strains of SARS-CoV-2.
“Crucially, it appears that efforts to eliminate and/or contain the virus are not likely to be successful. Therefore, it is critical that the role of containment efforts like quarantine and contact tracing is re-evaluated.”
The MAC also said the definition of “high risk” contact – those who “had face-to-face contact or [were] in a closed space with a Covid-19 case for at least 15 minutes” – was “based on an outdated understanding of the transmission dynamics” of the virus.
“The definition concentrates on droplet spread while ignoring aerosol spread, which can occur over distances greater than 1-1.5 metres, and also does not require as close a temporal association with the index case,” they wrote.
“In addition, it ignores the increased intrinsic transmissibility of subsequent variants of concern compared to the ancestral strain, as well as the fact that pre-existing immunity (from vaccination and/or natural infection) further changes the transmission dynamics.”
The experts said quarantining was not feasible in many social settings, and had a “substantial economic and social burden”.
Those include “significantly depleting” staffing levels at healthcare facilities and other frontline roles such as police, and “significantly reducing economic and governmental activities due to high levels of staff absenteeism”.
“We propose that quarantining be discontinued with immediate effect for contacts of cases of Covid-19,” they wrote.
“This applies equally to vaccinated and non-vaccinated contacts. No testing for Covid-19 is required irrespective of the exposure risk, unless the contact becomes symptomatic.
“We further propose that contact tracing be stopped.
“Since quarantining of contacts of cases no longer serves a public health role, identifying contacts of Covid-19 cases equally serves very little role. In addition, contact tracing is impractical once the Covid-19 caseload rises, and is extremely burdensome in its use of human and financial resources.”
The letter came as Mr Phaahla announced that South Africa would remain under modified “level one” lockdown restrictions over Christmas, amid concerns over the spread of the Omicron variant, News24 reported.
**************************************************
Daily Covid cases in South Africa have fallen for the fourth day in a row as Omicron continues to fade in the variant's original centre
Data from the National Institute For Communicable Diseases (NICD) shows 15,424 South Africans tested positive in the last 24 hours, down by a third on the nearly 24,000 cases confirmed last Tuesday.
A fifth fewer people were tested for the first in the last 24 hours compared to the same period last week, but test positivity — the proportion of those tested who are infected — has been trending downwards for eight days.
But hospitalisations and deaths – which lag two to three weeks behind the pattern seen in case numbers due to the delay in an infected person becoming seriously unwell – have risen.
More than 630 people were hospitalised across the country, up only 5 per cent in a week but the highest daily number in the country's fourth wave.
The previous record was last Wednesday when 620 people were hospitalised. Meanwhile 35 deaths were recorded, a 46 per cent uptick on last Tuesday.
The falling case numbers come despite only 25 per cent of South Africans being double-jabbed and boosters not being dished out in the country.
It raises hopes that the UK's Omicron wave will also be short-lived, with Britain also having a layer of protection in its booster programme.
It comes as UK scientists wait for data on how deadly the Omicron surge will be, with uncertainties about how severe it is and how well vaccines protect against serious outcomes.
But promisingly, cases already appear to be plateauing in the UK, with around 90,000 daily infections recorded for the last six days.
That's despite gloomy Government modelling warning that 1million Britons could be catching the virus daily by the end of the year.
Boris Johnson today said no to Christmas curbs because there is 'no evidence' on Omicron to justify it.
The NICD confirmed 55,877 people had been tested across South Africa in the last 24 hours and 15,424 (27.6 per cent) tested positive.
And test positivity dropped to 27.6 per cent, which is the lowest figure recorded in 10 days and marks the eighth day of infection rates trending downwards.
Britain's daily Covid cases have plateaued for the fifth day in a row as an expert claimed that the Omicron wave may have peaked already.
There were 90,629 infections in the past 24 hours across the UK, up 52 per cent on last Tuesday's toll but down slightly on the figure yesterday — despite wild projections of up to a million daily infections by New Year,
Cases have remained flat since last Friday when they hit a peak of more than 93,000.
In London, which has become a hotbed for Omicron, the wave also appears to be slowing. A total of 20,491 cases were recorded in the capital today, down slightly on yesterday's tally of 22,750.
The slowing statistics may be behind Boris Johnson's decision not to bring in tougher restrictions before Christmas , with the Prime Minister claiming today there was 'not enough evidence to justify' them.
Gloomy Government modelling presented to ministers last week said the mutant variant was doubling every two days and was infecting up to 400,000 daily by the weekend.
Professor Paul Hunter, an infectious diseases expert at the University of East Anglia, told MailOnline that Mr Johnson had made the right decision because cases 'look like they've peaked'.
He said: 'It's not all doom and gloom, it does look like Omicron has stopped growing. The numbers over the last few days seem to have plateaued and maybe even be falling.
'It's a bit too soon to be absolutely sure about that, but if it is the case Boris Johnson will breathe a sigh of relief. We have to be a little bit careful because it's only a few days.
'And because we're getting closer to Christmas there is nervousness that people may not come forward for testing because they don't want to test positive and miss out on meeting relatives.
'Omicron overtook the other variants around December 14 so most of any changes from there on would be down to Omicron. So if it was still doubling every two days that would have shown and we should have been at 200,000 cases yesterday and certainly more than 200,000 cases today.
'But the fact it has been around 91,000 raises the point that it might actually have peaked. But it will probably take until at least Wednesday to get an idea of a day that is not affected by the weekend. But I am more optimistic than I was a few days ago.'
Some 3.3million people in the country have tested positive since the pandemic began, but the true figure will be many millions more as not everyone who catches the virus is tested.
The majority of the new cases were recorded in Kwazulu-Natal (4,009), followed by Western Cape (3,324), as the virus spreads away from the ground zero Gauteng.
The province, which is home to Johannesburg and is where Omicron was first spotted, recorded the third-most cases (3,316).
Meanwhile, 633 people were hospitalised in the last day, up 5.7 per cent in a week, bringing the country’s total number of hospitalisations since the pandemic began to 459,844.
A total of 9,023 people are currently receiving hospital care.
And a further 35 Covid deaths were recorded, up 45.8 per cent on last Tuesday when 24 fatalities were registered.
The data from the country suggests the outbreak is fading around a month after it was first detected, while ministers and scientists in the UK are panicking about the impact the wave will have over the coming weeks.
And the UK has strengthened its response to the variant through its booster campaign, while third jabs have not been dished out in South Africa and just 23 per cent of its population are vaccinated.
However, UK experts have warned Britain's older and denser population is more susceptible to a big and deadly outbreak.
England's chief medical officer Professor Chris Whity last week said he expected to see the UK's daily cases rise extraordinarily due to Omicron, but also 'come down faster than previous peaks', mirroring South Africa's experience with the strain.
Professor Whitty told MPs on the Health and Social Care Committee last week: 'I think what we will see with this is — and I think we’re seeing it in South Africa — is that the upswing will be very incredibly fast even if people are taking more cautious action.
He added: 'It’ll probably therefore peak really quite fast.
'My anticipation is it may then come down faster than previous peaks but I wouldn’t want to say that for sure.'
It comes as Britain's daily Covid cases have plateaued for the fifth day in a row as an expert claimed that the Omicron wave may have peaked already.
There were 90,629 infections in the past 24 hours across the UK, up 52 per cent on last Tuesday's toll but down slightly on the figure yesterday — despite wild projections of up to a million daily infections by New Year.
Cases have remained flat since last Friday when they hit a peak of more than 93,000.
In London, which has become a hotbed for Omicron, the wave also appears to be slowing. A total of 20,491 cases were recorded in the capital today, down slightly on yesterday's tally of 22,750.
Professor Paul Hunter, an infectious diseases expert at the University of East Anglia, told MailOnline that Mr Johnson had made the right decision because cases 'look like they've peaked'.
He said: 'It's not all doom and gloom, it does look like Omicron has stopped growing. The numbers over the last few days seem to have plateaued and maybe even be falling.
'It's a bit too soon to be absolutely sure about that, but if it is the case Boris Johnson will breathe a sigh of relief. We have to be a little bit careful because it's only a few days.
*********************************************
Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS)
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Tuesday, December 21, 2021
Nasal spray developed by Australian scientists STOPS cancer patients catching Covid with a bigger trial to find if it can be the next weapon to fight the pandemic
Another one of those evil nasal sprays. But this one uses a well recognized therapeutic ingredient so will be harder to dismiss
A trial for a nasal spray that has prevented cancer patients getting Covid-19 could be a new weapon to fight the pandemic.
Some 175 patients have tested the drug by taking daily doses of a nasal spray containing cancer drug interferon developed by scientists at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital.
None of the participants in the C-SMART trial have contracted Covid so far, despite several waves of the virus plunging Melbourne into six lockdowns.
Scientists are seeking more volunteers to take part in the free trial, which will be expanded to Austin and St Vincent's hospitals in Melbourne, along with Westmead Hospital in western Sydney.
Anyone with a past or current cancer diagnosis is eligible to take part in the four month trial.
Scientists hope the nasal spray will be an extra protection for vulnerable patients until better preventions are developed.
'We have not had any patient on the trial actually report back to us that they have developed Covid infection,' National Centre for Infections in Cancer director Professor Monica Slavin told the Herald Sun.
'But we have had about 10 per cent of people on the trial sending in a swab due to some sort of viral illness.
'We know that there are groups of patients, because of the immune system being suppressed, that don't make a good response to the vaccination.'
But it hasn't all been smooth sailing for the trial, which began a year ago.
Scientists were forced to press pause on the trial for five months earlier this year when access to chemicals and sending samples of the drug for testing were hampered by international border closures.
The expanded trial will determine whether the drug can also prevent other respiratory viral illnesses.
Studies have shown cancer patients make up 10 per cent of severe Covid-19 cases, and about 20 per cent of those who die from it, according to the trial's website.
They are also more likely to rapidly develop severe infections and be admitted to ICU compared to cases without cancer.
*******************************************
Moderna says booster significantly increases antibodies against Omicron
Moderna announced Monday that a booster shot of its COVID-19 vaccine significantly increases antibody levels against the highly-transmissible Omicron variant.
A 50 microgram jab — the authorized dose for a third shot — saw a 37-fold increase in neutralizing antibodies, the vaccine maker said.
Moderna also tested a 100 microgram booster dose, which increased antibody levels 83-fold. The first two shots of Moderna’s vaccine are both 100 micrograms.
The company said the higher booster dose was generally safe and well-tolerated, although there was a trend toward slightly more frequent adverse reactions.
Moderna CEO Stephane Bancel called the data “reassuring” but said it will continue to “rapidly advance an omicron-specific booster candidate into clinical testing in case it becomes necessary in the future.”
However, for now, the drugmaker said the current version of its vaccine – mRNA-1273 — will continue to be its “first line of defense against Omicron.”
“What we have available right now is 1273,” Dr. Paul Burton, Moderna’s chief medical officer, told Reuters.
“It’s highly effective, and it’s extremely safe. I think it will protect people through the coming holiday period and through these winter months, when we’re going to see the most severe pressure of Omicron,” he added.
The data, which has not yet been peer-reviewed, tested blood from 20 booster recipients with each dose against a pseudovirus engineered to resemble the Omicron variant, the company said.
Antibody levels were measured on day 29 post-boost.
Burton said it would be up to governments and regulators to assess whether they want the enhanced level of protection that a 100 microgram dose might provide.
US regulators authorized Moderna’s 50 microgram booster in October.
***********************************************
Ancient Greek drug used to treat gout could reduce the risk of death from Covid-19 by as much as 50 per cent, study claims
A drug used to treat gout could hold the potential to cut the risk of death from Covid-19 by as much as 50 per cent, a new study claims.
Colchicine is an ancient drug derived from the Colchicum family of plants, which was first used for its special healing properties by the ancient Greeks.
It began to be widely used from about the first century AD as a treatment for gout and other inflammatory conditions, and is one of a few medicines that have survived into modern times, according to experts from the Hebrew University of Jerusalem.
Four controlled studies, involving 6,000 coronavirus patients, have been published into the effects of the drug, with each showing a 'clear benefit' from its use.
The Israeli researchers analysed the studies, finding 'significant improvement in severe coronavirus indices and, most importantly, there was a decrease in mortality by about 50 per cent compared to those who were not treated with colchicine.'
This is an important discovery, as the drug is cheap and requires just half a milligram dose per day, according to the researchers.
However, previous studies have found mixed results on the use of the drug, with some finding a significant benefit, as was the case here, and others finding none.
An Indian study from November found no benefit to using the drug to treat Covid-19.
What is colchicine? The 30p drug used to tackle gout
Colchicine is used to treat and prevent systemic inflammation, a feature of gout and the worst cases of coronavirus
Colchicine is a medicine for treating inflammation and pain. The pills are typically prescribed to treat flare-ups or attacks of gout
It is also used to prevent increased flare-ups of gout when a patient first starts on a medicine like allopurinol – taken to manage the condition in the long term.
Colchicine is also prescribed to prevent flare-ups of symptoms of familial Mediterranean fever (FMF) – an inherited inflammatory condition.
The usual dose for gout is one 0.5mg tablet, taken two to four times a day. Patients are advised to avoid grapefruit and grapefruit juice while taking colchicine.
Some patients find it is gentler on their stomach if they take the tablets with or after food.
It is not usually recommended in pregnancy or when breastfeeding.
For this new research, Prof Ami Schattner came at it from a different perspective, focusing on all patients treated in controlled trials with the ancient drug for any purpose over the past 20 years, rather than just treated for Covid-19.
Of the studies he reviewed, four focused on coronavirus and involved 6,000 patients, finding each saw a 'significant improvement' when using the drug.
Schattner says colchicine working to improve the outcome of Covid-19 patients is 'an important discovery that could significantly contribute to improving the morbidity and mortality of many patients, if confirmed in further studies.'
This is because, as well as being cheap, it is well-tolerated by patients with minimal side effects such as bouts of diarrhoea in 10 per cent of patients.
The studies used by the Israeli team were conducted around the world, including in Canada, Greece, Spain and Brazil.
They were all double-blind placebo studies, which make them more accurate, according to Schattner.
Further randomised trials are needed, involving the drug and Covid-19 patients, to confirm the results of this 'preliminary study', said Schattner.
He said that it is likely going to lead to an expansion of the use of low-dose colchicine in the treatment of coronavirus patients, and says there is 'no reason' that couldn't start now.
In November, an Indian research team from GMERS Medical College Gotri in Gujarat performed a meta-analysis of six studies that tested colchicine's ability to prevent severe cases of the virus.
'Colchicine does not reduce the risk of mortality, need for ventilatory support, intensive care unit admission or length of hospital stay among patients with Covid-19,' researchers wrote.
'There is no additional benefit of adding colchicine to supportive care in the management of patients with Covid-19.'
Four of the studies also researched whether the drug could reduce Covid-19 related hospital stays.
The combined results found no difference in mortality rates among people who used colchicine and those that did not.
In March a large British trial halted enrolments to test colchicine as a potential treatment for patients hospitalised with Covid-19.
This was after a sub-study of the trial found that the medication did not have any effect on the patients.
However, Schattner says his results are 'very promising' and worth exploring further.
'Even though initial data on the effect of colchicine on coronavirus patients is very promising, more patients need to be in randomised controlled trials,' Schattner told the Jerusalem Post.
'But that would not prevent me from using the drug already in patients with high risk, to hopefully lower their chances of developing severe disease.
'The drug is low-cost for the patients and the community,' he said. 'By using it in corona patients, we have nothing to lose and much to gain.'
A few gout drugs have been pointed to as potential Covid-19 treatments since the pandemic began.
Drugs used to treat gout often have anti-inflammatory properties, which can also reduce some of the side-effects of Covid-19.
Previous studies identified colchicine as a drug that could reduce inflammation related to Covid-19 and help patients.
Another anti-inflammatory drug used to treat gout, probenecid, has also showed a promising ability to combat Covid-19, though further research is needed.
*********************************************
Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS)
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Monday, December 20, 2021
Japan’s Vaccination Policy: No Force, No Discrimination
Japan’s ministry of health is taking a sensible, ethical approach to Covid vaccines. They recently labeled the vaccines with a warning about myocarditis and other risks. They also reaffirmed their commitment to adverse event reporting to document potential side-effects.
Japan’s ministry of health states: “Although we encourage all citizens to receive the COVID-19 vaccination, it is not compulsory or mandatory. Vaccination will be given only with the consent of the person to be vaccinated after the information provided.”
Furthermore, they state: “Please get vaccinated of your own decision, understanding both the effectiveness in preventing infectious diseases and the risk of side effects. No vaccination will be given without consent.”
Finally, they clearly state: “Please do not force anyone in your workplace or those who around you to be vaccinated, and do not discriminate against those who have not been vaccinated.”
They also link to a “Human Rights Advice” page that includes instructions for handling any complaints if individuals face vaccine discrimination at work.
Other nations would do well to follow Japan’s lead with this balanced and ethical approach.
This policy appropriately places the responsibility for this healthcare decision with the individual or family.
We can contrast this with the vaccine mandate approach adopted in many other Western nations. The United States provides a case study in the anatomy of medical coercion exercised by a faceless bureaucratic network.
A bureaucracy is an institution that exercises enormous power over you but with no locus of responsibility. This leads to the familiar frustration, often encountered on a small scale at the local DMV, that you can go round in bureaucratic circles trying to troubleshoot problems or rectify unfair practices. No actual person seems to be able to help you get to the bottom of things—even if a well-meaning person sincerely wants to assist you.
Here’s how this dynamic is playing out with coercive vaccine mandates in the United States. The CDC makes vaccine recommendations. But the ethically crucial distinction between a recommendation and mandate immediately collapses when institutions (e.g., a government agency, a business, employer, university, or school) require you to be vaccinated based on the CDC recommendation.
Try to contest the rationality of these mandates, e.g., in federal court, and the mandating institution just points back to CDC recommendation as the rational basis for the mandate. The court will typically agree, deferring to the CDC’s authority on public health. The school, business, etc., thus disclaims responsibility for the decision to mandate the vaccine: “We’re just following CDC recommendations, after all. What can we do?”
But CDC likewise disclaims responsibility: “We don’t make policy; we just make recommendations, after all.”
Meanwhile, the vaccine manufacturer is immune and indemnified from all liability or harm under federal law. No use going to them if their product—a product that you did not freely decide to take—harms you.
You are now dizzy from going round in circles trying to identify the actual decision-maker: it’s impossible to pinpoint the relevant authority. You know that enormous power is being exercised over your body and your health, but with no locus of responsibility for the decision and no liability for the outcomes.
You are thus left with the consequences of a decision that nobody claims to have made. The only certainty is that you did not make the decision and you were not given the choice.
******************************************************
People who get breakthrough COVID-19 infections after being fully vaccinated have 'super immunity' with antibody levels rising as much as 2,000%, study finds
A new study finds that those who get a breakthrough COVID-19 infection after being fully vaccinated may acquire 'super immunity' from another infection.
The small study compared 26 vaccinated staff at Oregon Health & Science University who had breakthrough infections to people who were vaccinated but never got the coronavirus.
The breakthrough group saw a surge in antibodies.
'The increases were substantial, up to a 1,000 percent increase and sometimes up to 2,000 percent, so it's really high immunity,' said study author Fikadu Tafesse, a molecular microbiology and immunology professor at OHSU in Portland, Oregon.
'It's almost "super immunity."'
Cases of Omicron, thought to be more infectious than other variants - almost doubled from Friday to Saturday, with the variant confirmed in all but six US states.
Meanwhile, a Columbia University study found that patients given a booster shot of either Pfizer or Moderna had 6.5 times fewer antibodies for Omicron than the original virus - meaning boosters alone may not be as protective.
The efficacy of a regular course of the three vaccines approved in the US waned significantly after six months in a study conducted by the Public Health Institute in Oakland, California
'The bottom line of the study is that vaccine provides you with foundational immunity for whatever comes next,' Tafesse told USA Today, cautioning that no one should purposefully seek to get infected with COVID-19.
Various studies show that being infected and getting a dose of a COVID vaccine is very effective against COVID, but this is one of the few that consider the reverse scenario.
'This is one of the first that shows a breakthrough infection following vaccination generates stronger immunity than prior infection or vaccination alone,' said Dr. Monica Gandhi of the University of California at San Francisco.
She warns that getting the virus first isn't recommended because 'we cannot predict who will get very ill with COVID.'
'What we're saying is, we know life happens. If you happen to be exposed to the virus, you'll have this amazing immune response,' Tafesse said. 'It mirrors the immunity response we get to the booster.'
Getting a booster may provide crucial protection against Omicron, according to a study by a team at the Public Health Institute in Oakland, California released last month.
The Pfizer-BioNTech jab - which is far and away the most commonly used in the US - saw its effectiveness drop from 87 percent in March to 43 percent in September.
Moderna's shot held up the best, and is the only one of the three to still be more than 50 percent effective.
The shot's effectiveness has still fallen greatly, though, from 89 percent in March to 58 percent in September.
Johnson & Johnson vaccine recipients are especially at risk with just 13 percent efficacy against contracting the virus.
Meanwhile, Columbia University study looked at people given a booster of one of the two mRNA vaccines and found that boosted people had 6.5 times fewer antibodies for Omicron than the original virus.
It was less of a drop than that of people who only got a normal two-dose course. There was a 21-fold drop in neutralizing antibodies against Omicron after two doses of Pfizer compared to the original strain and a 8.6-fold drop with Moderna's jabs.
The study has not been peer-reviewed or published in a scientific journal.
Omicron already accounts for about three percent of cases nationwide and 13 percent of cases in the New York/New Jersey area, according to recent modeling data from the Centers for Disease Control.
On Saturday, New York state reported that the number of Omicron cases in New York City - the epicenter of the first wave of the pandemic - was 192, though there are likely more, New York Magazine reports.
On Saturday, New York reported 21,908 cases of COVID-19 throughout the state, a slight uptick from Friday's 21,027 new cases, which was already a new single-day record.
The CDC maintains that vaccines continue to be effective against the worst outcomes of COVID-19.
'With other variants, like Delta, vaccines have remained effective at preventing severe illness, hospitalizations, and death. The recent emergence of Omicron further emphasizes the importance of vaccination and boosters,' the CDC says.
The agency says Omicron will 'likely' spread more easily than the original SARS-CoV-2 virus, but it's not known how much easier it spreads than the Delta variant, which sent cases soaring late this summer.
Santacon - which sees thousands of costumed revelers trawl the bars of the East Village and Lower East Side - could have contributed to the rise of cases in New York City.
Mark Levin, the chair of the city's health commission, said the December 11 event could've been a factor. 'Manhattan unfortunately now has highest covid rate in NYC,' he tweeted Saturday. 'This is partly because we test more. But this should serve as a warning about how much Omicron is out there.
'Be especially cautious about indoor gatherings where masks come off. (And yes SantaCon may partly be to blame.)'
On social media, many said that they had tested positive since attending SantaCon, and others reacted with fury to the event having been held in the first place.
As of Saturday morning, there were 830 cases of the Omicron COVID-19 variant confirmed by DNA sequencing across the country, a 97 percent increase from Friday morning's tally.
In reality, the true number of Omicron cases is much higher, as only 1 to 2 percent of all cases are sequenced for variant markers, but the testing data shows a disturbing national trend.
Testing has now confirmed the presence of Omicron in every US state except for Oklahoma, Montana, North and South Dakota, Indiana and Vermont, though the eventual confirmation of the highly transmissible variant in every state now seems assured.
On Sunday, Joe Biden's chief medical advisor contradicted the vice president, who had claimed that no one saw the Omicron variant coming. 'We did. We definitely saw variants coming,' said Dr. Anthony Fauci, after being read Kamala Harris's quote.
On Friday, Harris told the Los Angeles Times: 'We didn't see Delta coming. I think most scientists did not - upon whose advice and direction we have relied — didn't see Delta coming. 'We didn't see Omicron coming. And that's the nature of what this, this awful virus has been, which as it turns out, has mutations and variants.'
Fauci said that Harris was mistaken - but he accepted that Omicron's potency had not been forecast. 'What was not anticipated was the extent of the mutations and the amino acid substitutions in Omicron, that is really is unprecedented and came out of nowhere,' Fauci told CNN's Jake Tapper, on State of the Union.
'When you have a virus which has 50 mutations. 'To me that is really quite unprecedented so that is something you would not have anticipated.
*********************************************
Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS)
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Sunday, December 19, 2021
We cannot stop the spread of COVID, but we CAN end the pandemic: Protect the old and vulnerable, forget lockdowns - and learn to live with the virus
By Jay Bhattacharya, MD, PhD a professor at the Stanford University School of Medicine. This is about what I have been saying all along
The arrival of the omicron variant has led some politicians and public health grandees to call for a return to business closures and 'circuit-breaker' lockdowns.
The variant has been found worldwide, including in the US and the UK. The variant has already surpassed delta – dominant before omicron – in the UK.
Early reports from South Africa confirm that the variant is more transmissible but produces a milder disease, with a lower chance of hospitalization and death upon infection.
My message is this: we can’t stop the spread of COVID, but we can end the pandemic.
In October 2020, I wrote the Great Barrington Declaration (GBD) along with Prof. Sunetra Gupta of Oxford University and Prof. Martin Kulldorff of Harvard University.
The centerpiece of the declaration is a call for increased focused protection of the vulnerable older population, who are more than a thousand times more likely to die from COVID infection than the young.
We can protect the vulnerable without harming the rest of the population.
As I stated above, we do not have any technology that can stop viral spread. While excellent vaccines protect the vaccinated versus hospitalization or death if infected, they provide only temporary and marginal protection from infection and disease transmission.
The same is likely true for booster shots, which use the same technology as the initial doses.
What about lockdowns? It is now abundantly clear that they have failed to contain the virus while wreaking enormous collateral damage worldwide.
The simplistic allure of lockdowns is that we can break the chain of viral transmission by staying apart.
Only the laptop class -- those who can just as easily work from home as in the office -- can abide by a lockdown in actual practice, and even they have trouble.
Essential workers who keep society going cannot afford the luxury, so the disease will keep spreading.
Will the same policies that failed against a more virulent strain succeed in containing a more transmissible strain? The answer is self-evidently no.
The harms of lockdown on children and the non-elderly are catastrophic, including worse physical and mental health and irretrievably lost life opportunities.
Lockdowns imposed in rich countries mean starvation, poverty, and death for the residents of poor countries.
There is, however, a good alternative to lockdown. The Great Barrington Declaration (GBD) calls for a return to normal life for low-risk children and non-elderly adults.
The principles at the heart of the GBD are as important today as they were a year ago. In fact, they are more important now because we now have technological tools that make focused protection of the vulnerable much more straightforward than it was a year ago.
First and most importantly, the vaccine.
Because unvaccinated older people face such a high risk for a poor outcome on infection, and because the vaccine is so effective at blunting severe disease and death, vaccinating older people is the top priority if life-saving is to be the top priority.
But to preserve doses, they should be reserved for those who have not previously had COVID and were vaccinated more than 6 to 8 months ago.
According to a careful study conducted by Swedish scientists, vaccine efficacy versus severe disease also starts to wane around that point, so boosting before then does not provide a substantial benefit.
Second, we should make available effective early treatment options.
During Florida’s summer wave, Gov. Ron DeSantis promoted the use of monoclonal antibodies – an FDA-approved treatment – by patients early in the course of the disease, an action that saved many lives.
Safe and inexpensive supplements like Vitamin D have been shown effective. Promising new treatments from Pfizer and a new antibody treatment for the immunocompromised by Astra Zeneca promise to become more widely available. Until that happens, they should be preserved for use by the most vulnerable when sick.
Third, the widespread availability of inexpensive, privately conducted, rapid antigen tests in the UK has empowered everyone to make wise choices that reduce the risk of infecting vulnerable people. So far, the FDA says that these tests work to detect omicron.
Even if you have no COVID-like symptoms, these tests accurately read whether you harbor the virus and pose a risk of spreading it to close contacts. With this test in hand, anyone can check if it is safe to visit grandma before heading over to her care home. It is a perfect tool for focused protection of the vulnerable. US COVID policy should focus on making these tests cheaper and more widely available, as they are in the UK.
Finally, since the virus very often spreads via aerosolization events, upgrades to ventilation systems in public spaces will reduce the risk of older people participating in everyday social life outside the home.
It is no accident that COVID disease spread is so rare on airplanes since they are all outfitted with excellent air filtration systems. Upgrading other public facilities, such as other public transportation systems, would reduce the risk of infection for the vulnerable.
There are some hopeful signs that the political and ideological winds are shifting, while other developments signal a return to failed strategies.
Colorado's Democrat Governor Jared Polis recently declared that the widespread availability of vaccines spells ‘the end of the medical emergency,’ and he is resisting calls to impose new statewide mask mandates.
Yet on the coasts, in California and New York, elected officials are renewing mask requirements for all – regardless of health or vaccination status.
The end of the pandemic is primarily a social and political decision.
Since we have no technology to eradicate the virus, we must learn to live with it. The fear-based lockdown policies of the past two years are no template for a healthy society.
The good news is that with the new and effective technologies available and the focused protection ideas outlined in the GBD, we can end the pandemic if only we can muster the courage and political will to do so.
In Sweden and many US states that have eschewed lockdowns, the pandemic is effectively over, even as the virus continues to circulate.
As normal society resumes, the vast majority will find that living with the virus is not so hard after all.
**************************************************
Many omicron cases at Cornell in fully vaccinated: official
Cornell University is seeing an uptick in coronavirus cases and has detected the “highly contagious” omicron variant on campus, particularly in fully vaccinated individuals, according to campus officials.
Between Dec. 7 and 13, the Ivy League school in Ithaca, New York, reported 883 students testing positive for COVID-19, its online dashboard shows.
“Virtually every case of the Omicron variant to date has been found in fully vaccinated students, a portion of whom had also received a booster shot,” Joel M. Malina, the school’s vice president for university relations, said in a statement provided to McClatchy News.
On Dec. 13, Cornell’s COVID-19 testing lab found “evidence of the highly contagious Omicron variant in a significant number of Monday’s positive student samples,” university President Martha E. Pollack said in a letter to the campus community.
Out of the students infected with COVID-19, the school has “not seen severe illness” as of Dec. 14, Pollack assured.
The on-campus population of Cornell is 97% fully vaccinated, according to its virus data tracker that has recorded 26,008 students and 13,311 faculty and staff members who are fully vaccinated.
Pollack noted that the evidence of omicron, first identified by South African researchers on Nov. 24, is “preliminary.”
“PCR testing has identified its hallmark (the so-called S-gene dropout) in a substantial number of virus samples,” Pollack said. “While we must await confirmatory sequencing information to be sure that the source is Omicron, we are proceeding as if it is.”
*******************************************************
Omicron easier on the lungs, British study suggests
Omicron may be less efficient at replicating in the lungs than previous COVID variants, British laboratory research has suggested.
A study conducted by scientists at the Cambridge Institute of Therapeutic Immunology and Infectious Disease found that mutations on the virus’s spike protein, which make it able to evade antibodies, may also reduce its ability to attack the lungs and cause severe disease.
“We demonstrate significantly lower infectivity of lung organoids and Calu-3 lung cells,” says the Cambridge preprint, which was posted late on Friday night.
“These observations highlight that Omicron has gained immune evasion properties whilst compromising on properties associated with replication and pathogenicity [harm].”
The study was led by Ravi Gupta, professor of clinical microbiology at the University of Cambridge and a contributor to Scientific Advisory Group for Emergencies.
“The Omicron spike protein induces relatively poor [lung] cell-cell fusion compared to Wuhan and Delta,” said Gupta, announcing the findings on Twitter. “The difference is significant.”
Gupta said the findings could point to Omicron causing less severe disease but said more work was needed.
“In summary this work suggests that Omicron does appear to have become more immune evasive, but that properties associated with disease progression may be attenuated [weakened] to some extent,” he said. “The significant growth of Omicron nevertheless represents a major public health challenge”.
Scientists are rushing to understand if Omicron is more severe in unvaccinated people than previous variants. The signals are mixed.
Early data on hospital admissions and deaths from South Africa suggest that Omicron is so far doing significantly less damage there than previous waves. A hospital group reported last week that 29 per cent fewer adults were being admitted to hospital than in the Delta wave, and far fewer of those required intensive care.
On the other hand, there was a 20 per cent jump in the number of children being hospitalised, and a double dose of Pfizer vaccine was shown to be just 70 per cent effective at preventing hospital admissions, falling further in the old.
Professor Chris Whitty, the Chief Medical Officer for England, warned against “overinterpretation” of the South African data last week, noting its population was much younger and with more prior exposure to COVID than our own.
“The amount of immunity for this wave because of prior Delta wave and vaccination is far higher than it was for their last wave and, therefore the fact they have a lower hospitalisation rate this time is unsurprising.”
*********************************************
Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS)
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Friday, December 17, 2021
Omicron is 'markedly resistant' to COVID vaccines and boosters shots may only give 'slight protection', Columbia University study finds
In a study published Wednesday by Dr. David Ho and 20 other researchers, the scientists discovered that Omicron's 'extensive' mutations can 'greatly compromise' all major COVID-19 vaccines - Pfizer, Moderna, Johnson & Johnson and AstraZeneca - even neutralizing them.
The report also found that while booster shots provided an additional layer of protection, the variant 'may still pose a risk' for those who get the third shot.'
'These findings are in line with emerging clinical data on the Omicron variant demonstrating higher rates of reinfection and vaccine breakthroughs,' the scientists wrote.
'Even a third booster shot may not adequately protect against Omicron infection.'
The study looked at the effectiveness of each major vaccine against the Omicron variant, finding several cases where they failed to provide the needed protection against infection.
While the booster shots proved to be overall consistent, some recorded instanced put it right at the threshold of actually being effective.
Ho and the Columbia research team, who worked along side the University of Hong Kong, said the study delivers a grave warning about the future of COVID and its variants.
'It is not too far-fetched to think that this [COVID-19] is now only a mutation or two away from being pan-resistant to current antibodies,' the researchers wrote.
'We must devise strategies that anticipate the evolutional direction of the virus and develop agents that target better conserved viral elements.'
The warning came as confirmed US Omicron cases jumped by a third overnight, from 241 on Wednesday to 319 on Thursday. But experts have warned those are the tip of the iceberg, and that American cases likely already number in the tens of thousands.
White House COVID tsar Dr. Anthony Fauci even remarked on the variant's 'extraordinary' ability to spread, before revealing that cases will double every three days.
The number of people testing positive in New York also has doubled in three days, from 3.9 per cent of all swabs coming back positive on December 9, to 7.8 per cent on December 12. More than four fifths of New York
Bill de Blasio's senior public health adviser Dr. Jay Varman, a Cornell epidemiology professor, tweeted the news, saying: 'Um, we've never seen this before in #NYC. Test positivity doubling in three days.'
A total of 81 per cent of New Yorkers are fully-vaccinated, and 18.5 per cent have received their booster shots - but a worrying new study from Columbia University suggests that neither may be sufficient in protecting from Omicron.
Immunologists have also forecast a potential triple-whammy of Omicron, Delta and regular flu infections this winter. Two doctors interviewed by DailyMail.com said those who haven't received a booster shot should consider returning to Spring 2020-style self-isolation, when COVID's Alpha variant raged through the US, and no vaccines were available.
Speaking on Good Morning America on Thursday, Fauci also confirmed Omicron was on track to be the dominant Covid strain in America within weeks.
He said: 'Certainly what [Omicron] is showing us in other countries [is that it spreads faster than other variants] and I believe soon in our own country.
'It has an extraordinary ability to transmit efficiently and spread. It has what we call a doubling time of around three days.
'And if you do the math on that, if you have just a couple of percentage of the isolates being Omicron, very soon it's going to be the dominant variant. We've seen that in South Africa, we're seeing it in the U.K. and I'm absolutely certain that's what we're going to be seeing here relatively soon.'
The doubling time of three days is slightly longer than the 2.5 days reported by British and South African health officials. On Thursday, the UK recorded its second-consecutive day of record infections - 88,376 - 24 hours after Wednesday's total of 78,610. That is a 74 per cent jump in a week, with 15 people who've been infected with Omicron so-far hospitalized in the UK.
The US is much larger, with most of its landmass not as densely populated as the UK or South Africa.
But Omicron is believed to represent up to 13 per cent of new diagnoses in New Jersey and New York - states with extremely well-populated areas - giving a possible early taste of what's to come with the new strain.
Fauci continues to urge Americans to get vaccinated, and boosted, to protect themselves from the virus, especially now with the new threat of Omicron circulating. A total of 16.5 per cent of Americans have so-far had the booster shot.
'We need to do everything that we have been talking about up to now, and even more so,' he said.
He spoke hours after the CDC agency released forecasts on Wednesday night showing that weekly Covid cases will increase by 55 percent to 1.3 million per week - or 185,714 per day - by Christmas.
It also predicted deaths will jump by 73 percent to up to 15,600 per day by early January - or 2,228 deaths per day.
Some of that predicted surge is already appearing in parts of the country, with Florida revealing 6,381 new cases on Thursday - the state's largest single day Covid increase since September.
The Delta variant is still the dominant Covid strain in the U.S., accounting for around 97 percent of sequenced cases. Omicron is quickly making up ground, though, with the newly discovered variant jumping seven-fold in a week from making up 0.4 percent of cases to 2.9 percent of case, according to the most recent CDC data.
Lori Tremmel Freeman, chief executive officer of the National Association of County and City Health Officials, has warned of a nightmare scenario where Delta, Omicron and regular seasonal flu could combine to inflict the winter from hell on US hospitals already struggling to cope with an influx of patients.
She told CNN: 'It's the combination. It's kind of the perfect storm of public health impacts here with Delta already impacting many areas of the country and jurisdictions. We don't want to overwhelm systems more.'
Early data also shows that people who are only fully vaccinated, but have not yet received their booster, are still extremely vulnerable to the virus, with Johnson & Johnson's single-dose shot offering effectively no protection.
Booster shots have been deemed effective against the variant, though, with both Moderna and Pfizer revealing data in recent days showing their vaccines will cause massive increases in antibody levels and up to 75 per cent protection from Covid symptoms.
But confusion remains about just how effective boosters are against a strain that was only identified after Americans began receiving them en-masse.
A new study by Columbia University in New York, published on Thursday, said: 'Even serum from persons vaccinated and boosted with mRNA-based vaccines exhibited substantially diminished neutralizing activity against (omicron),'
Only around 16.5 percent of Americans have received the additional vaccine dose so far though - as they were not widely available until late November - meaning that more than 80 percent of Americans are at risk from Omicron.
Dr Chris Thompson is an infectious disease expert at Loyola University of Maryland. He told DailyMail.com on Thursday that people who have not received their booster dose yet may want to bring back some early pandemic habits like social distancing, masking, frequent hand washing and more.
'The data that I've seen says that you're about 33 percent protected after a two dose regimen of either of the mRNA vaccines [the Pfizer or Moderna shots] and we don't have good data from Johnson and Johnson's vaccine yet. Then if you get your booster you look like you get back up into the 75 percent protection range and for preventing disease'
Whether Delta or Omicron, U.S. is experiencing yet another surge of Covid cases during the holiday season. The nation is recording 121,188 new cases every day - a 40 percent increase over the past two weeks. Deaths are making a sharp rise as well, up 34 percent to 1,302 per week.
The number of Americans hospitalized with the virus increased over the past 14 days as well, up 21 percent to 68,079. The Centers for Disease Control and Prevention projects that the situation will only worsen as well.
*************************************************
Johnson & Johnson's COVID vaccine produces virtually NO antibody protection against Omicron variant in lab study
A new study has found that Johnson & Johnson's COVID-19 vaccine produced virtually no antibody response to the Omicron variant.
South African virologist Penny Moore found that a key measure of antibody levels fell fell from 303 against the original strain to undetectable levels against Omicron in those with the J&J shot, according to Bloomberg.
Among those who received the Pfizer shot, the antibody measure, called geometric mean titers, fell from 1,419 against the original coronavirus strain to 80 against Omicron.
'Omicron does indeed exhibit substantial immune escape from antibodies,' she in a presentation on Tuesday. 'The situation, I think, is even more alarming for the J&J vaccine -- there was no detectable neutralization in our assay.'
Confirmed US Omicron case numbers sit at 241 as of Wednesday, up 27 per cent from the 189 recorded the day before, according to data from various state reporting bodies.
But CDC officials have warned the true scale of Omicron infection is far higher, with around three per cent of all US COVID cases now caused by the variant, or up to 13 per cent in New York and New Jersey.
Meanwhile, Cornell University in upstate New York is now suspected of being home to the largest Omicron outbreak in the US so far, with more than 900 infections, which experts anticipate will almost all have been caused by Omicron.
The J&J study was conducted under test-tube conditions with human blood plasma and has not yet been published.
It does not rule out other immune responses to Omicron in those with the J&J vaccine, such as from powerful T cells.
*************************************
Is Omicron running out of steam in South Africa? Daily Covid cases rise by just 10% in a week and hospital admissions DROP for first time since strain took off
South Africa's daily Covid cases rose by just 10 per cent in a week today while hospitalisations fell for the first time since Omicron mutant strain first took off.
Data from the National Institute for Communicable Diseases showed 24,785 cases were recorded in the last 24 hours, up 11 per cent on last Thursday.
It is the second smallest week-on-week rise since South African doctors raised the alarm about the variant on November 24. Cases rose by just 5 per cent in a week this past Saturday.
The NICD data shows there were 347 admissions today, down almost a quarter from 507 a week ago. It marks the first time since November 27 that admissions have declined. Just 36 Covid deaths were registered today compared to 22 last Thursday.
Scientists have cautioned against reading into one day of data but there are increasing signs that South Africa's Omicron crisis may not be growing exponentially anymore, and may have peaked.
In another promising sign, infections fell in ground zero Gauteng province by 42 per cent in a week, with 6,744 positive tests.
Today is a public holiday in South Africa, which may have played a role in the relatively low infection and hospital numbers. But there were still 80,000 tests processed today, down only slightly on yesterday.
South African scientists have been saying for weeks that the super-mutant variant is milder than its rivals, and calling on other nations including Britain not to over-react to the strain.
*********************************************
Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS)
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Thursday, December 16, 2021
More hope from ground zero: Cases in Omicron-stricken South African province are FALLING
Omicron infections may have already peaked in the South African epicentre, fresh data suggested today as an ex-Government Covid adviser claimed the UK's incoming outbreak may be no worse than flu.
The South African Government's weekly Covid surveillance report revealed that cases fell in Gauteng province last week for the first time since the nation sounded the alarm about Omicron on November 24.
There were 377 cases per 100,000 people in the week to December 11 in Gauteng, down roughly 4 per cent on the previous week. Experts told MailOnline that while the 'encouraging' drop in cases was small enough to be within the margin of error, it at the very least shows Omicron is no longer spreading exponentially.
Testing in the province has more than doubled in the past three weeks — from 541 tests per 100,000 on November 27 to 1,264 now, suggesting swabbing capacity is not the issue.
Professor Robert Dingwall, a former member of the Nervtag and JCVI panels, expects the ultra-infectious variant to infect so many Britons that it creates a work absence crisis. But he predicted that it won't overwhelm the NHS, despite gloomy warnings from No10's own scientists.
A major real-world study of Omicron in South Africa yesterday found that the mutant virus is causing two-thirds fewer hospital admissions than Delta, bolstering claims it is milder than previous strains.
Professor Dingwall, a sociologist who still sits on the Government's Moral and Ethical Advisory Group but has no input on the response to the pandemic, told MailOnline: 'Respectable experts in South Africa are telling us we're overreacting and that this is a milder virus.
He accused British scientists of 'snobbery', adding: 'The best South African scientists are as good as scientists anywhere in world and if their view is there no reason to panic, we shouldn't be so quick to disagree.'
Doctors on the ground in the South Africa have insisted for weeks that Omicron causes milder disease, likely due to immunity from earlier waves and vaccines. There are just 375 daily Covid admissions in South Africa currently, on average.
Professor Dingwall told The Telegraph last night: 'My gut feeling is that omicron is very much like the sort of flu pandemic we planned for – a lot of sickness absence from work in a short period, which will create difficulties for public services and economic activity, but not of such a severity as to be a big problem for the NHS and the funeral business.'
His comments come as a weekly Covid report from South Africa's National Institute for Communicable Diseases found cases dropped in Gauteng last week for the first time.
The province, which includes major cities like Johannesburg and Tshwane, recorded 377 cases per 100,000 people in the week to December 11, down 3.9 per cent on the previous week.
The development comes after the first major real-world study in South Africa found that Omicron is currently leading to a third fewer hospital admissions than Delta did during its entire wave — 38 admissions per 1,000 Omicron cases compared to 101 per 1,000 for Delta.
Officials who analysed 78,000 Omicron cases in the past month estimated the risk of hospitalisation was a fifth lower than with Delta and 29 per cent lower than the original virus.
The findings lend weight to the theory that the ultra-infectious variant is weaker than previous strains, something which doctors on the ground in South Africa have been claiming for weeks.
But the reduction in severity is probably not solely down to Omicron being intrinsically milder, according to the South African Medical Research Council which led the analysis.
Around 70 per cent of South Africans have recovered from Covid already and 23 per cent are double-vaccinated, which has created high levels of immunity.
The study also found two doses of Pfizer's vaccine still provide 70 per cent protection against hospital admission or death from Omicron, compared to 93 per cent for Delta.
While this is more protection than many scientists initially feared, it still leaves 30 per cent of people vulnerable to severe Omicron disease, four times as many as Delta. Waning immunity from two Pfizer doses was found to offer just 33 per cent protection against Omicron infection, explaining why the country has seen a meteoric rise in case numbers.
*******************************************
Where I Live, No One Cares About COVID
This is pretty true of where I live too -- in the Australian State of Queensland. No-one chips you if you don't wear a mask or you don't check in.
The article below appeared in The Atlantic, a left-leaning mag. Many of their readers were enraged
By Matthew Walther
Outside the world inhabited by the professional classes in a handful of major metropolitan areas, many Americans are leading their lives as if COVID is over.
In November, my wife asked me whether I had seen an article with the remarkable headline “Is It Safe to Go to Thanksgiving Dinner?”
“Is that from last year?” I asked.
“No, it’s a few days old,” she said, her voice sinking to a growling murmur. “These people.”
I am old enough to remember the good old days when holiday-advice pieces were all variations on “How to Talk to Your Tea Party Uncle About Obamacare.” As Christmas approaches, we can look forward to more of this sort of thing, with the meta-ethical speculation advanced to an impossibly baroque stage of development. Is it okay for our 2-year-old son to hug Grandma at a Christmas party if she received her booster only a few days ago? Should the toddler wear a mask except when he is slopping mashed potatoes all over his booster seat? Our oldest finally attended her first (masked) sleepover with other fully vaccinated 10-year-olds, but one of them had a sibling test positive at day care. Should she stay home or wear a face shield? What about Omicron?
I don’t know how to put this in a way that will not make me sound flippant: No one cares. Literally speaking, I know that isn’t true, because if it were, the articles wouldn’t be commissioned. But outside the world inhabited by the professional and managerial classes in a handful of major metropolitan areas, many, if not most, Americans are leading their lives as if COVID is over, and they have been for a long while.
In my part of rural southwest Michigan, and in similar communities throughout the country, this is true not despite but without any noticeable regard for cases; hospitalization statistics, which are always high this time of year without attracting much notice; or death reports. I don’t mean to deny COVID’s continuing presence. (For the purposes of this piece, I looked up the COVID data for my county and found that the seven-day average for positive tests is as high as it has ever been, and that 136 deaths have been attributed to the virus since June 2020.) What I wish to convey is that the virus simply does not factor into my calculations or those of my neighbors, who have been forgoing masks, tests (unless work imposes them, in which case they are shrugged off as the usual BS from human resources), and other tangible markers of COVID-19’s existence for months—perhaps even longer.
Indeed, in my case, when I say for a long while, I mean for nearly two years, from almost the very beginning. In 2020, I took part in two weddings, traveled extensively, took family vacations with my children, spent hundreds of hours in bars and restaurants, all without wearing a mask. This year my wife and I welcomed our fourth child. Over the course of her pregnancy, from the first phone call to the midwife a few months after getting a positive pregnancy test until after delivery, the subject of the virus was never raised by any health-care professional, including her doula, a dear friend from New York.
Meanwhile, our children, who have continued to attend their weekly homeschooling co-op since April 2020, have never donned masks, and they are distinctly uncomfortable on the rare occasions when they see them, for reasons that, until recently, child psychologists and other medical experts would have freely acknowledged. They have continued seeing friends and family, including their great-grandparents, on a weekly basis. As far as I can tell, they are dimly aware that “germs” are a remote cause of concern, but only our oldest, who is 6, has any recollection of the brief period last year when public Masses were suspended in our diocese and we spent Sunday mornings praying the rosary at home.
The CDC recommends that all adults get a booster shot; I do not know a single person who has received one. When I read headlines like “Here’s Who May Need a Fourth COVID-19 Vaccine Dose,” I find myself genuinely reeling. Wait, there are four of them now? I would be lying if I said I knew what all the variants were or what differences exist between them. (They all sound like the latest entry in some down-market action franchise: Tom Clancy’s Delta Variant: A Jack Ryan Novel, Transformers 4: Rise of the Omicron.) COVID is invisible to me except when I am reading the news, in which case it strikes me with all the force of reports about distant coups in Myanmar.
Granted, my family’s experience of 2020 was somewhat unusual. But I wager that I am now closer to most of my fellow Americans than the people, almost absurdly overrepresented in media and elite institutions, who are still genuinely concerned about this virus. And in some senses my situation has always been more in line with the typical American’s pandemic experience than that of someone in New York or Washington, D.C., or Los Angeles.
The best example of this fact, apart from the agita about holiday travel, is outdoor masking. Prescinding from the question of whether there was ever any meaningful evidence in favor of outdoor transmission, let me point out that until I found myself in Washington, D.C., on a work trip in March, I had never seen anyone wearing a mask outside. For someone who had never worn one in any situation, it was bizarre to find thousands of people indifferently donning these garments outdoors, including those walking alone or in pairs at night after leaving bars or restaurants where they had presumably taken them off. It was even stranger seeing people recognize one another in the street and pull their masks down casually, sometimes but not always before stopping to engage in conversation, like Edwardian gentlemen doffing their top hats.
I came away from this experience with the impression that, whatever their value, masks long ago transcended public health and became a symbol, not unlike in this house we believe signs or MAGA hats. This, no doubt, is why in my part of America, the only people one ever sees with masks are brooding teenagers seated alone in coffee shops, who seem to have adopted masks to set themselves apart from the reactionary banality of life in flyover country in the same way that I once scribbled anti-Bush slogans on T-shirts. The survival of such old-fashioned adolescent angst is, at any rate, deeply heartening.
As far as my wife and I are concerned, an atmosphere of parochialism hangs upon relentless adherence to CDC directives. By European standards, hand-wringing about masks in schools is as silly and absurdly risk-averse as the American medical establishment’s insistence that pregnant women not drink coffee or wine. Indeed, there is something small-minded and puritanical and distinctly American about the whole business of obsessing over whether vaccinated teachers remove their face covering during a long school day. (When I read such things, I experience the same secondhand embarrassment I felt upon witnessing an American tourist in Rome ask a waiter at a trattoria to remove the ashtray from the outdoor table at which the employee in question had just been smoking.)
I am always tempted to ask the people who breathlessly quote what various public-health authorities are now saying about masking and boosters whether they know how the National Institutes of Health defines a “problem drinker”? The answer is a woman who has more than one “unit” of alcohol a day, i.e., my wife and nearly all of my female friends. These same authorities, if asked, would probably say that considerable risks are associated with eating crudos or kibbeh nayyeh, or taking Tylenol after a hangover. (This is to say nothing of cannabis, which is of course still banned at the federal level.) My point is that sophisticated adults are generally capable of winking at overly stringent guidelines. In the case of COVID, many are not.
I wish I could convince myself that for once in my life with COVID we were actually experiencing a healthy break from the usual pattern, according to which the latest silly novelties—no-fault divorce, factory-sliced bread, frozen meals, and, of course, infant formula—are adopted enthusiastically by the upper middle classes, who then think better of them by the time the lower orders come around.
But I am afraid that the future, at least in major metropolitan areas, is one in which sooner or later elites will acknowledge their folly while continuing to impose it on others. I, for one, would not be surprised if for years to come it were the expectation in New York and California that even vaccinated workers in the service industry wear masks, the ultimate reification of status in a world in which casual dress has otherwise erased many of what were once our most visible markers of class.
After all, you never know how they spent their Thanksgiving.
https://www.theatlantic.com/ideas/archive/2021/12/where-i-live-no-one-cares-about-covid/620958/
*************************************Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS)
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Wednesday, December 15, 2021
Good news at last! Omicron is causing up to a THIRD fewer hospitalisations than Delta and two Pfizer jabs still slash death risk of severe disease by 70%
Omicron is causing milder disease than Delta in patients in the epicentre of the new Covid variant, the first major real-world study in South Africa confirmed today.
Officials who analysed 78,000 Omicron cases in the past month estimated the risk of hospitalisation was a fifth lower than with Delta and 29 per cent lower than the original virus.
As a crude rate, Omicron is currently leading to a third fewer hospital admissions than Delta did during its entire wave — 38 admissions per 1,000 Omicron cases compared to 101 per 1,000 for Delta.
The findings lend weight to the theory that the ultra-infectious variant is weaker than previous strains, something which doctors on the ground in South Africa have been claiming for weeks.
But the reduction in severity is probably not solely down to Omicron being intrinsically milder, according to the South African Medical Research Council which led the analysis.
Around 70 per cent of South Africans have recovered from Covid already and 23 per cent are double-vaccinated, which has created high levels of immunity.
The finding will raise hopes that the UK's Omicron wave will be less severe than previous peaks, despite having an older and denser population. Unlike South Africa, the UK is rolling out booster jabs on a mass scale.
The study also found two doses of Pfizer's vaccine still provide 70 per cent protection against hospital admission or death from Omicron, compared to 93 per cent for Delta.
While this is more protection than many scientists initially feared, it still leaves 30 per cent of people vulnerable to severe Omicron disease, four times as many as Delta. Waning immunity from two Pfizer doses was found to offer just 33 per cent protection against Omicron infection, explaining why the country has seen a meteoric rise in case numbers.
Against Delta, two Pfizer jabs initially offer more than 80 per cent protection against symptomatic infection before falling to around 60 per cent within six months.
Today's study, co-run by private health insurance company Discovery Health, was based on more than 211,000 positive Covid test results from November 15 to December 7, 78,000 of which were attributed to Omicron.
Overall, four in 10 of those who tested positive had received two doses of the Pfizer/BioNTech vaccine.
The 70 per cent protection from severe disease figure still puts two doses well above the World Health Organization's efficacy threshold of 50 per cent.
But the researchers said that efficacy was reduced further in older age groups, falling to just 59 per cent in the 70 to 79 bracket, for example.
That could be because older people were vaccinated first in the initial rollout and there has been more time for immunity to wane than in younger people.
Protection against admission was consistent across a range of chronic illnesses including diabetes, hypertension, hypercholesterolemia, and other cardiovascular diseases, the study said.
Children appeared to have a 20 per cent higher risk of hospital admission with complications during the fourth wave than during the first, despite the numbers still being tiny.
'This is early data and requires careful follow up,' said Shirley Collie, chief health analytics actuary at Discovery Health.
She cautioned that children were still 51 per cent less likely to test positive during the Omicron wave and the risk for them remains low.
As a crude rate, Omicron is currently causing a third fewer hospital admissions than Delta did — 38 admissions per 1,000 Omicron cases, compared to 101 per 1,000 for Delta.
However, South Africa is only a month into its Omicron outbreak and Covid admissions are steadily rising, with 422 admitted yesterday, a rise of 141 per cent compared to last week.
A total of 6,198 people are being treated for the virus now compared to the 5,562 who were in hospital on Sunday — the biggest single-day rise since the new variant took off.
Yet, despite the increasing case and hospital numbers, there were just 11 deaths attributed to Covid in the last 24 hours, up only marginally on last week.
Doctors in South Africa's Omicron ground zero maintain that Omicron patients are coming in with milder illness and being discharged quicker.
Official figures suggest the number of Covid hospital patients with severe illness is a third of the level at the same point in the country's Delta wave.
The South African doctor who first raised the alarm about Omicron last month endorsed the study today, telling MPs that it confirmed what doctors were seeing on the ground.
Dr Angelique Coetzee, chairwoman of the South African Medical Association, told the Commons Science and Technology Committee that 'we don't have all the answers' but the clinical picture so far is that people are mostly suffering mild illness from Omicron.
Dr Coetzee said some people are getting breakthrough infections if they are vaccinated or if they have had Covid before, but cases seemed to be milder, especially for the vaccinated.
'The breakthrough infections we are seeing are mild... (and) the symptoms we are seeing in (vaccinated) people are less severe or intense than in the unvaccinated,' she said.
'On a hospital level... between 88 per cent to 90 per cent (of people) are unvaccinated.'
She said that in hospitals it is hard to differentiate between those patients with the Delta variant and those with Omicron, but that intensive care units 'are still not overwhelmed'.
Pfizer's Covid pill slashes the risk of hospitalisation and death by up to 90 per cent and will work against Omicron, the vaccine maker claimed today.
A study of more than 2,200 at-risk adults found the drug, called Paxlovid, reduced the risk of severe outcomes by 89 per cent.
And a separate trial of the pill, which the UK has already ordered 250,000 doses of, on healthy unvaccinated adults found taking it within a few days of suffering Covid symptoms cuts the chance of being hospitalised by 70 per cent, Pfizer said.
Meanwhile, laboratory tests suggest Paxlovid will still offer a 'robust' response against the Omicron variant, which is due to become dominant in the UK tomorrow.
Pfizer's boss Dr Albert Bourla said the emergence of Omicron has ‘exacerbated the need for accessible treatment options for those who contract the virus’ and the pill could be a ‘critical tool to help quell the pandemic’.
The UK's medicines regulator has so far approved one at-home pill in the fight against Covid. But molnupiravir, made by US-based Merck and Ridgeback, will only be given to older and at-risk people within 48 hours of catching the virus as part of a pilot that is expected to launch by the end of the year.
He added: 'For example, the narrative around South Africa is that Omicron may be much milder, whereas reports out of Denmark broadly suggests the opposite.
'This reflects the uncertainty of new data. Within that, factors include the different levels of exposure to Covid-19 and previous infection, levels of vaccination and potential waning of immunity, and also age ranges infected thus far.
'We know that Covid-19 is very adept at moving from younger to older populations within a few weeks.
*****************************************************
Irish firm collaborating on delivery of world’s first inhaled COVID-19 vaccine
After months of collaborative work in the lab, China's CanSino Biologics and Irish drug delivery specialist Aerogen are taking their inhaled COVID-19 vaccine pact to the next stage.
CanSino and Aerogen are teaming up to develop and market an inhaled version of CanSino's recombinant COVID-19 shot Convidecia, which is already approved in China as a one-and-done injectable. Because aerosol delivery requires a "considerably smaller volume of vaccine," the partners' inhaled prospect could help stretch capacity and enable more patients to access the inoculation, the companies said.
Outside of China, Convidecia boasts emergency authorizations in countries such as Argentina, Chile, Ecuador, Indonesia, Hungary and Pakistan. The shot is around 63.7% effective against COVID-19 two weeks after vaccination, and 96% effective against severe disease over that same time frame, a CanSino representative said during an October World Health Organization presentation. At 28 days, overall efficacy dropped to 57.5%, while efficacy in severe disease hovered around 91.7%.
As for the inhaled candidate, CanSino's vaccine will leverage Aerogen's vibrating mesh aerosol drug delivery technology, the companies said. The aerosolized vaccine is directly inhaled through a cup dispenser into the patient's airway, mimicking the respiratory virus's natural infection pathway. This delivery route could further help patients, thanks to the potential for mucosal immunity, the partners said.
*************************************
Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS)
http://snorphty.blogspot.com/ (TONGUE-TIED)
*************************************
Subscribe to:
Posts (Atom)
